These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 1497422

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years.
    Hershfield MS.
    Clin Immunol Immunopathol; 1995 Sep; 76(3 Pt 2):S228-32. PubMed ID: 7554473
    [Abstract] [Full Text] [Related]

  • 4. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency.
    Hershfield MS.
    Hum Mutat; 1995 Sep; 5(2):107-12. PubMed ID: 7749407
    [Abstract] [Full Text] [Related]

  • 5. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase.
    Chun JD, Lee N, Kobayashi RH, Chaffee S, Hershfield MS, Stiehm ER.
    Ann Allergy; 1993 Jun; 70(6):462-6. PubMed ID: 8507039
    [Abstract] [Full Text] [Related]

  • 6. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
    Weinberg K, Hershfield MS, Bastian J, Kohn D, Sender L, Parkman R, Lenarsky C.
    J Clin Invest; 1993 Aug; 92(2):596-602. PubMed ID: 8349799
    [Abstract] [Full Text] [Related]

  • 7. Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA).
    Hershfield MS.
    Immunodeficiency; 1993 Aug; 4(1-4):93-7. PubMed ID: 8167743
    [No Abstract] [Full Text] [Related]

  • 8. [Polyethylene glycol-adenosine deaminase: a new adenosine deaminase deficiency therapy. Value of deoxyadenosine triphosphate determination for therapeutic monitoring].
    Bory C, Boulieu R, Souillet G, Hershfield MS.
    Therapie; 1991 Aug; 46(4):323-6. PubMed ID: 1948809
    [Abstract] [Full Text] [Related]

  • 9. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy.
    Hershfield MS, Chaffee S, Sorensen RU.
    Pediatr Res; 1993 Jan; 33(1 Suppl):S42-7; discussion S47-8. PubMed ID: 8433874
    [Abstract] [Full Text] [Related]

  • 10. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
    Chan B, Wara D, Bastian J, Hershfield MS, Bohnsack J, Azen CG, Parkman R, Weinberg K, Kohn DB.
    Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907
    [Abstract] [Full Text] [Related]

  • 11. Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase.
    Kaufman DA, Hershfield MS, Bocchini JA, Moissidis IJ, Jeroudi M, Bahna SL.
    Pediatrics; 2005 Dec; 116(6):e876-9. PubMed ID: 16263974
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency.
    Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS.
    J Clin Invest; 1992 May; 89(5):1643-51. PubMed ID: 1569204
    [Abstract] [Full Text] [Related]

  • 14. A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency.
    Bax BE, Bain MD, Fairbanks LD, Webster AD, Ind PW, Hershfield MS, Chalmers RA.
    Eur J Haematol; 2007 Oct; 79(4):338-48. PubMed ID: 17680812
    [Abstract] [Full Text] [Related]

  • 15. Chondroosseous dysplasia in severe combined immunodeficiency due to adenosine deaminase deficiency (chondroosseous dysplasia in ADA deficiency SCID).
    Chakravarti VS, Borns P, Lobell J, Douglas SD.
    Pediatr Radiol; 1991 Oct; 21(6):447-8. PubMed ID: 1749685
    [Abstract] [Full Text] [Related]

  • 16. Effect of polyethylene glycol-modified adenosine deaminase (PEG-ADA) therapy in two ADA-deficient children: measurement of erythrocyte deoxyadenosine triphosphate as a useful tool.
    Bory C, Boulieu R, Souillet G, Chantin C, Guibaud P, Hershfield MS.
    Adv Exp Med Biol; 1991 Oct; 309A():173-6. PubMed ID: 1789201
    [No Abstract] [Full Text] [Related]

  • 17. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency.
    Blaese RM.
    Pediatr Res; 1993 Jan; 33(1 Suppl):S49-53; discussion S53-5. PubMed ID: 8433875
    [Abstract] [Full Text] [Related]

  • 18. Management options: SCIDS with adenosine deaminase deficiency.
    Hilman BC, Sorensen RU.
    Ann Allergy; 1994 May; 72(5):395-403; quiz 403-4, 407. PubMed ID: 8179225
    [Abstract] [Full Text] [Related]

  • 19. Pegademase bovine: replacement therapy for severe combined immunodeficiency disease.
    Lee CR, McKenzie CA, Webster KD, Whaley R.
    DICP; 1991 Oct; 25(10):1092-5. PubMed ID: 1803799
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.